SPARC Promotes Pericyte Recruitment Via Inhibition of Endoglin-dependent TGF-β1 Activity

Overview

Journal J Cell Biol

Specialty Cell Biology

Date 2011 Jun 29

PMID 21708981

Citations 35

Authors

Lee B Rivera

Rolf A Brekken

Affiliations

Soon will be listed here.

Abstract

Pericytes migrate to nascent vessels and promote vessel stability. Recently, we reported that secreted protein acidic and rich in cysteine (SPARC)-deficient mice exhibited decreased pericyte-associated vessels in an orthotopic model of pancreatic cancer, suggesting that SPARC influences pericyte behavior. In this paper, we report that SPARC promotes pericyte migration by regulating the function of endoglin, a TGF-β1 accessory receptor. Primary SPARC-deficient pericytes exhibited increased basal TGF-β1 activity and decreased cell migration, an effect blocked by inhibiting TGF-β1. Furthermore, TGF-β-mediated inhibition of pericyte migration was dependent on endoglin and αV integrin. SPARC interacted directly with endoglin and reduced endoglin interaction with αV integrin. SPARC deficiency resulted in endoglin-mediated blockade of pericyte migration, aberrant association of endoglin in focal complexes, an increase in αV integrins present in endoglin immunoprecipitates, and enhanced αV integrin-mediated activation of TGF-β. These results demonstrate that SPARC promotes pericyte migration by diminishing TGF-β activity and identify a novel function for endoglin in controlling pericyte behavior.

Citing Articles

Anti-Tumor Effects of Sheep Umbilical Cord Mesenchymal Stem Cells on Melanoma Cells.

Yue F, Zhao Y, Lv Y, Li S, Wang W, Li Y Int J Mol Sci. 2025; 26(1.

PMID: 39796281 PMC: 11720557. DOI: 10.3390/ijms26010426.

Signaling Role of Pericytes in Vascular Health and Tissue Homeostasis.

Fazio A, Neri I, Koufi F, Marvi M, Galvani A, Evangelisti C Int J Mol Sci. 2024; 25(12).

PMID: 38928298 PMC: 11203602. DOI: 10.3390/ijms25126592.

HDAC10 inhibition represses melanoma cell growth and BRAF inhibitor resistance via upregulating SPARC expression.

Ling H, Li Y, Peng C, Yang S, Seto E NAR Cancer. 2024; 6(2):zcae018.

PMID: 38650694 PMC: 11034028. DOI: 10.1093/narcan/zcae018.

GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs.

Ji Q, Zhu H, Qin Y, Zhang R, Wang L, Zhang E Front Pharmacol. 2024; 15:1329636.

PMID: 38323081 PMC: 10844528. DOI: 10.3389/fphar.2024.1329636.

ROS impairs tumor vasculature normalization through an endocytosis effect of caveolae on extracellular SPARC.

Zhao Y, Yu J, Huang A, Yang Q, Li G, Yang Y Cancer Cell Int. 2023; 23(1):152.

PMID: 37528424 PMC: 10394868. DOI: 10.1186/s12935-023-03003-8.

References

Lyons R, Keski-Oja J, Moses H . Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol. 1988; 106(5):1659-65. PMC: 2115066. DOI: 10.1083/jcb.106.5.1659. View

Delannet M, Martin F, Bossy B, Cheresh D, Reichardt L, Duband J . Specific roles of the alpha V beta 1, alpha V beta 3 and alpha V beta 5 integrins in avian neural crest cell adhesion and migration on vitronectin. Development. 1994; 120(9):2687-702. PMC: 2710119. DOI: 10.1242/dev.120.9.2687. View

Bourdeau A, Dumont D, Letarte M . A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest. 1999; 104(10):1343-51. PMC: 409846. DOI: 10.1172/JCI8088. View

Ray B, Lee N, How T, Blobe G . ALK5 phosphorylation of the endoglin cytoplasmic domain regulates Smad1/5/8 signaling and endothelial cell migration. Carcinogenesis. 2010; 31(3):435-41. PMC: 2832549. DOI: 10.1093/carcin/bgp327. View

Klemke R, Yebra M, Bayna E, Cheresh D . Receptor tyrosine kinase signaling required for integrin alpha v beta 5-directed cell motility but not adhesion on vitronectin. J Cell Biol. 1994; 127(3):859-66. PMC: 2120222. DOI: 10.1083/jcb.127.3.859. View

Weaver M, Workman G, Sage E . The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin beta1 and activation of integrin-linked kinase. J Biol Chem. 2008; 283(33):22826-37. PMC: 2504874. DOI: 10.1074/jbc.M706563200. View

Arnold S, Rivera L, Miller A, Carbon J, Dineen S, Xie Y . Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis Model Mech. 2009; 3(1-2):57-72. PMC: 2806901. DOI: 10.1242/dmm.003228. View

Nie J, Chang B, Traktuev D, Sun J, March K, Chan L . IFATS collection: Combinatorial peptides identify alpha5beta1 integrin as a receptor for the matricellular protein SPARC on adipose stromal cells. Stem Cells. 2008; 26(10):2735-45. PMC: 4066418. DOI: 10.1634/stemcells.2008-0212. View

Goumans M, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C . Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell. 2003; 12(4):817-28. DOI: 10.1016/s1097-2765(03)00386-1. View

10.

Raines E, Lane T, Iruela-Arispe M, Ross R, Sage E . The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc Natl Acad Sci U S A. 1992; 89(4):1281-5. PMC: 48433. DOI: 10.1073/pnas.89.4.1281. View

11.

Galliher A, Schiemann W . Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res. 2006; 8(4):R42. PMC: 1779461. DOI: 10.1186/bcr1524. View

12.

Lane T, Iruela-Arispe M, Sage E . Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1. J Biol Chem. 1992; 267(23):16736-45. View

13.

Reznikoff C, Brankow D, HEIDELBERGER C . Establishment and characterization of a cloned line of C3H mouse embryo cells sensitive to postconfluence inhibition of division. Cancer Res. 1973; 33(12):3231-8. View

14.

Guasch G, Schober M, Pasolli H, Conn E, Polak L, Fuchs E . Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell. 2007; 12(4):313-27. PMC: 2424201. DOI: 10.1016/j.ccr.2007.08.020. View

15.

Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D . Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003; 111(9):1287-95. PMC: 154450. DOI: 10.1172/JCI17929. View

16.

Barker T, Baneyx G, Cardo-Vila M, Workman G, Weaver M, Menon P . SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J Biol Chem. 2005; 280(43):36483-93. DOI: 10.1074/jbc.M504663200. View

17.

Gerhardt H, Semb H . Pericytes: gatekeepers in tumour cell metastasis?. J Mol Med (Berl). 2007; 86(2):135-44. DOI: 10.1007/s00109-007-0258-2. View

18.

Munger J, Harpel J, Giancotti F, Rifkin D . Interactions between growth factors and integrins: latent forms of transforming growth factor-beta are ligands for the integrin alphavbeta1. Mol Biol Cell. 1998; 9(9):2627-38. PMC: 25536. DOI: 10.1091/mbc.9.9.2627. View

19.

Motamed K, Sage E . SPARC inhibits endothelial cell adhesion but not proliferation through a tyrosine phosphorylation-dependent pathway. J Cell Biochem. 1998; 70(4):543-52. DOI: 10.1002/(sici)1097-4644(19980915)70:4<543::aid-jcb10>3.0.co;2-i. View

20.

Hasselaar P, Sage E . SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. J Cell Biochem. 1992; 49(3):272-83. DOI: 10.1002/jcb.240490310. View